Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38683| Title: | Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-beta | Authors: | Simpson-Yap, Steve PIRMANI, Ashkan DE BROUWER, Edward PEETERS, Liesbet GEYS, Lotte PARCIAK, Tina Helme, Anne Hillert, Jan Moreau, Yves Edan, Gilles Spelman, Tim Sharmin , Sifat McBurney, Robert Schmidt, Hollie Bergmann, Arnfin Braune, Stefan Stahmann, Alexander Middleton, Rodden Salter, Amber Bebo, Bruce van der Walt, Anneke Butzkueven, Helmut Ozakbas, Serkan Karabudak, Rana Boz, Cavit Alroughani, Raed Rojas, Juan, I van der Mei, Ingrid do Olival, Guilherme Sciascia Magyari, Melinda Alonso, Ricardo Nicholas, Richard Chertcoff, Anibal Zabalza, Ana Arrambide, Georgina Nag, Nupur Descamps, Annabel Costers, Lars Dobson, Ruth Miller, Aleisha Rodrigues, Paulo Prckovska, Vesna Comi, Giancarlo Kalincik, Tomas |
Issue Date: | 2022 | Publisher: | ELSEVIER SCI LTD | Source: | Multiple sclerosis and related disorders (Print), 66 (Art N° 104072) | Abstract: | Background: Interferon-beta, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS. Results: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs. Conclusions: In comparison to other DMTs, we did not find evidence of protective effects of interferon-beta on the severity of COVID-19, though compared to the untreated, the course of COVID-19 was milder among those on interferon-beta. This study does not support the use of interferon-beta as a treatment to reduce COVID-19 severity in MS. | Notes: | Simpson-Yap, S (corresponding author), Univ Melbourne, Dept Med, CORe, Melbourne, Vic, Australia.; Simpson-Yap, S (corresponding author), Univ Melbourne, Melbourne Sch Populat & Global Hlth, Neuroepidemiol Unit, Melbourne, Vic, Australia.; Simpson-Yap, S (corresponding author), Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia. steve.simpsonyap@unimelb.edu.au |
Document URI: | http://hdl.handle.net/1942/38683 | ISSN: | 2211-0348 | e-ISSN: | 2211-0356 | DOI: | 10.1016/j.msard.2022.104072 | ISI #: | 000850461000003 | Rights: | 2022 Elsevier B.V. All rights reserved. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β.pdf Restricted Access | Published version | 405.02 kB | Adobe PDF | View/Open Request a copy |
| Auteursversie.pdf | Peer-reviewed author version | 321.3 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.